AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,907 | -43.3% | 1,046 | -47.6% | 0.00% | -33.3% |
| Q2 2023 | $93,287 | +62091.3% | 1,998 | -49.2% | 0.00% | -40.0% |
| Q1 2023 | $150 | +29.3% | 3,935 | +84.5% | 0.01% | 0.0% |
| Q4 2022 | $116 | -99.7% | 2,133 | +106.9% | 0.01% | +400.0% |
| Q3 2022 | $35,000 | -54.5% | 1,031 | -87.4% | 0.00% | -50.0% |
| Q2 2022 | $77,000 | -76.5% | 8,167 | -64.6% | 0.00% | -33.3% |
| Q1 2022 | $328,000 | +786.5% | 23,058 | +1215.3% | 0.00% | +200.0% |
| Q4 2021 | $37,000 | -7.5% | 1,753 | -2.1% | 0.00% | 0.0% |
| Q3 2021 | $40,000 | -41.2% | 1,791 | -34.9% | 0.00% | -50.0% |
| Q2 2021 | $68,000 | +161.5% | 2,752 | +211.3% | 0.00% | – |
| Q1 2021 | $26,000 | -73.5% | 884 | -76.8% | 0.00% | -100.0% |
| Q4 2020 | $98,000 | +100.0% | 3,806 | +141.2% | 0.00% | +200.0% |
| Q3 2020 | $49,000 | +28.9% | 1,578 | +2.3% | 0.00% | -50.0% |
| Q2 2020 | $38,000 | +171.4% | 1,542 | +126.1% | 0.00% | +100.0% |
| Q1 2020 | $14,000 | -79.4% | 682 | -77.6% | 0.00% | -83.3% |
| Q4 2019 | $68,000 | +161.5% | 3,049 | +120.8% | 0.01% | +200.0% |
| Q2 2019 | $26,000 | – | 1,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |